Panelists:

Image of Ehsan Malek, MD

Ehsan Malek, MD

Associate Professor of Medicine
Director of the Multiple Myeloma Translational Research Program
Roswell Park Comprehensive Cancer Center

Panelist

Image of Ehsan Malek, MD

Ehsan Malek, MD

Ehsan Malek, MD, is a leading expert in the care and research of multiple myeloma and related plasma cell disorders at Roswell Park Comprehensive Cancer Center in Buffalo, NY. With over a decade of clinical experience, Malek specializes in comprehensive treatment approaches, including immunotherapy, stem cell transplantation, and cutting-edge cellular therapies. As director of the Multiple Myeloma Translational Research Program and associate professor of oncology, he is deeply involved in advancing new therapeutic strategies that aim to improve outcomes and quality of life for patients with complex or high-risk disease. Malek also focuses on innovations such as minimal residual disease (MRD) testing and novel immune-based treatments. Known for his patient-centered approach and commitment to both clinical care and research innovation, Malek brings deep expertise, compassion, and leadership to the multiple myeloma community.

Image of Juan José Garcés, PhD

Juan José Garcés, PhD

Postdoctoral Researcher
Memorial Sloan Kettering Cancer Center

Panelist

Image of Juan José Garcés, PhD

Juan José Garcés, PhD

Juan José Garcés, PhD, is a postdoctoral research scholar at Memorial Sloan Kettering Cancer Center in New York. His research focuses on advancing minimally invasive strategies to better understand and monitor multiple myeloma. Garcés completed his undergraduate studies in biochemistry and molecular biology at the University of the Basque Country in Spain. He went on to earn a master’s degree in clinical pharmacy and a PhD from the University of Navarra, where his doctoral research contributed to the development of innovative liquid biopsy approaches in multiple myeloma. At Memorial Sloan Kettering, Garcés leverages genomic and computational tools to develop and evaluate minimally invasive clinical approaches, primarily focused on liquid biopsies, with the aim of improving patient outcomes through precision medicine. His recent article in HemaSphere examines the association between circulating tumor cells, proliferative activity, and genomic complexity in multiple myeloma.

Image of C. Michael Osborne, MS, CGC

C. Michael Osborne, MS, CGC

Medical Science Liaison
Menarini Silicon Biosystems

Panelist

Image of C. Michael Osborne, MS, CGC

C. Michael Osborne, MS, CGC

C. Michael Osborne is a certified genetic counselor and clinical science liaison with Menarini Silicon Biosystems. In this role, he partners with healthcare professionals to provide clinical and scientific expertise focused on minimally invasive liquid biopsy technologies. He completed his undergraduate studies at the University of North Carolina at Chapel Hill before earning a master of science in genetic counseling from the University of North Carolina at Greensboro in 2011. Following graduation, he spent three years in direct patient care and served on faculty at the University of North Carolina at Chapel Hill School of Medicine, contributing to clinical education and training. Since transitioning into the diagnostics industry in 2014, Osborne has focused on supporting clinicians and laboratory teams through education and implementation guidance related to genomic testing and liquid biopsy applications in oncology.

Broadcast Date: 
  • Time: 

Plasma cell neoplasms, including multiple myeloma (MM), collectively represent the third most diagnosed hematologic malignancy in the United States. Although primarily a disease of the bone marrow, plasma cell neoplasms frequently exhibit peripheral egression, with circulating multiple myeloma cells (CMMCs) detectable in the blood of about 98% of newly diagnosed patients.

A growing body of evidence demonstrates that CMMCs reflect overall disease biology—including bone marrow tumor burden, underlying genomic architecture, and disease activity. These findings support the continued deployment of minimally invasive, guideline-acknowledged complementary tools for assessing patient prognostication, disease progression and remission monitoring, and assessment of treatment response.

In this Inside Precision Medicine webinar, our expert speakers will discuss the rapidly evolving landscape of multiple myeloma diagnosis, treatment, and monitoring—with an emphasis on advancements in minimally invasive, guideline-acknowledged tools. During the webinar, they will explore the clinical utilities of peripheral blood plasma cell enumeration in multiple myeloma and its precursor conditions. They will also review anticipated updates to the International Myeloma Working Group (IMWG) Disease Response Criteria, including a new response category that requires an assessment for circulating plasma cells as part of its revised multimodal monitoring approach.

A live Q&A session followed the presentation offering a chance to pose questions to our expert panelists.

Produced with support from:

Menarini/Silicon Bio logo
Also of Interest